SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Boston Scientific Corporation (BSX) trades at a trailing P/E of 31.7, forward P/E of 18.5. Trailing earnings yield is 3.16%, forward earnings yield 5.42%. PEG 0.57 (Peter Lynch undervalued ≤1.0). Graham Number is $26.90.
Criteria proven by this page:
- VALUE (51/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 18.5 (down from trailing 31.7) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.57 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.16% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.42% as earnings recover.
- Analyst consensus target $108.35 (+69.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 80/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
51/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BSX
Valuation Multiples
P/E (TTM)31.7
Forward P/E18.5
PEG Ratio0.57
Forward PEG0.24
P/B Ratio3.78
P/S Ratio4.57
EV/EBITDA20.8
Per Share Data
EPS (TTM)$1.95
Forward EPS (Est.)$3.46
Book Value / Share$16.51
Revenue / Share$13.54
FCF / Share$2.44
Yields & Fair Value
Earnings Yield3.16%
Forward Earnings Yield5.42%
Dividend Yield0.00%
Graham Number$26.90
SharesGrow IV$103.80 (+62.6%)
Analyst Target$108.35 (+69.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
84.6 |
-0.35 |
4.36 |
3.50 |
- |
| 2017 |
326.6 |
-4.72 |
4.84 |
3.75 |
- |
| 2018 |
29.2 |
0.02 |
5.59 |
4.97 |
- |
| 2019 |
13.4 |
0.07 |
4.53 |
5.86 |
- |
| 2020 |
-621.1 |
6.07 |
3.32 |
5.14 |
0.05% |
| 2021 |
58.1 |
-0.06 |
3.63 |
5.08 |
0.09% |
| 2022 |
94.8 |
-2.69 |
3.77 |
5.22 |
0.08% |
| 2023 |
52.7 |
0.37 |
4.36 |
5.90 |
0.03% |
| 2024 |
70.9 |
4.27 |
6.04 |
7.85 |
- |
| 2025 |
48.9 |
0.88 |
5.82 |
7.03 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.25 |
$8.39B |
$347M |
4.1% |
| 2017 |
$0.07 |
$9.05B |
$104M |
1.1% |
| 2018 |
$1.19 |
$9.82B |
$1.67B |
17% |
| 2019 |
$3.33 |
$10.74B |
$4.7B |
43.8% |
| 2020 |
$-0.10 |
$9.91B |
$-140M |
-1.4% |
| 2021 |
$0.69 |
$11.89B |
$1.04B |
8.8% |
| 2022 |
$0.45 |
$12.68B |
$698M |
5.5% |
| 2023 |
$1.07 |
$14.24B |
$1.59B |
11.2% |
| 2024 |
$1.25 |
$16.75B |
$1.85B |
11.1% |
| 2025 |
$1.94 |
$20.07B |
$2.89B |
14.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$3.47 |
$3.42 – $3.51 |
$22.25B |
$22.15B – $22.69B |
18 |
| 2027 |
$3.91 |
$3.79 – $3.98 |
$24.59B |
$24.25B – $25.19B |
18 |
| 2028 |
$4.44 |
$4.06 – $4.92 |
$27.09B |
$27.03B – $27.16B |
4 |
| 2029 |
$4.98 |
$4.91 – $5.13 |
$29.74B |
$29.42B – $30.42B |
2 |
| 2030 |
$5.61 |
$5.53 – $5.78 |
$33.07B |
$32.71B – $33.83B |
2 |
